Pharmacological therapies with incretin-based ‘multi-agonists’ are rapidly advancing the therapeutic landscape for obesity. The loss of skeletal muscle mass with these potent weight-loss agents is emerging as a possible side effect. It is therefore important to determine whether multi-agonists increase the risk of sarcopenia in susceptible patients.

中文翻译：

---

肥胖药物治疗中的骨骼肌缺失和肌肉减少症


基于肠促胰岛素的“多激动剂”的药物治疗正在迅速推动肥胖症的治疗前景。这些强效减肥药导致骨骼肌质量的减少正在成为一种可能的副作用。因此，确定多种激动剂是否会增加易感患者发生肌肉减少症的风险非常重要。